English
officinas cellaemagni momenti locum obtinent in cultura cellularum magnarum, praecipue adhibitis in veneficiis, productionibus vaccinis, therapiis cellis et aliis agris. Cellulae magis sensitivae sunt ad ambitum productionis, sic necessariae consumabiles sunt etiam relative altae. Deprehensio biologica magni ponderis est deprehensio fundamentalis, maxime in iis quae sequuntur:
cytotoxicitatis experimentum: merae cellae occisiones eventus causantur cellis vel oeconomiae quae apoptosin vel necrosi tamquam cellae mortis machinamenta non nituntur. Per hanc probationem iudicari potest an materias rudium officinarum cella contineant substantias quae ad incrementum cellae non conducunt immunes responsiones specificas producere ad eos. damnum, manifesta indicia et signa ostendens. Per hanc probationem iudicari potest an substantia test allergen sit et intensio sensilizationis.
Hemolysis test: Hemolysis probatio est methodus protegendi ac identificatio bacterii in norma nationali specificata. Communiter in identificatione Streptococci, Vibrio, Diphtheriae, etc. Multae bacteria hemolysin producere possunt, quae laminam hemolyticam facere potest, ergo anulus hemolyticus circa has bacteria apparebit.
Ratio toxicitatis probatio: Principium systemicae toxicitatis probatio. est considerare potentias adversas effectus producti vel materiales leaching in usu medicinae machinis. Quia haec excerpta textuum vel organorum, quae non sunt directa contactu cum facto per effusionem, distributionem et metabolismum corporis humani, laedere possunt.
Praeterea experimentum biologicum etiam stimulationis intradermalis experimenti et reactionis intradermalis experimentum includit. Testimenta haec omnia sunt ut officina cellularum substantias non contineat quae incrementum cellae afficiunt, ut normalem cellularum multiplicationem curent.
In addition, the biological test also includes intradermal stimulation test and intradermal reaction test. These test items are all to ensure that the cell factory does not contain substances that affect cell growth, so as to ensure the normal proliferation of cells.
The FAI climbed 5.9 percent year-on-year in the first 11 months of 2018, quickening from the 5.7-percent growth in Jan-Oct, the National Bureau of Statistics (NBS) said Friday in an online statement.
The key indicator of investment, dubbed a major growth driver, hit the bottom in August and has since started to rebound steadily.
In the face of emerging economic challenges home and abroad, China has stepped up efforts to stabilize investment, in particular rolling out measures to motivate private investors and channel funds into infrastructure.
Friday's data showed private investment, accounting for more than 60 percent of the total FAI, expanded by a brisk 8.7 percent.
NBS spokesperson Mao Shengyong said funds into weak economic links registered rapid increases as investment in environmental protection and agriculture jumped 42 percent and 12.5 percent respectively, much faster than the average.
In breakdown, investment in high-tech and equipment manufacturing remained vigorous with 16.1-percent and 11.6-percent increases respectively in the first 11 months. Infrastructure investment gained 3.7 percent, staying flat. Investment in property development rose 9.7 percent, also unchanged.